By Dr Georges Muller (SEED Biosciences Ltd)2024-04-12T10:00:33
CRISPR has transformed gene editing, but still presents challenges in hard-to-transfect cells, such as pluripotent stem cells and primary cells.1 The key to obtaining successful transfection in these cells lies in innovative workflows. Here Georges Müller, CEO and cofounder of SEED Biosciences, shares his perspective on why focusing on editing ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2023-01-04T16:08:55
Sponsored by Sartorius Incucyte® Live-Cell Analysis System
2023-03-28T11:38:32
Sponsored by Bio-Techne
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
2023-09-27T13:56:39
Sponsored by Euretos
2023-03-23T14:46:21
Sponsored by Bio-Techne
2024-01-19T07:40:55
Sponsored by Euretos
Site powered by Webvision Cloud